These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 22988875)
21. ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease. Verma M; Steer EK; Chu CT Biochim Biophys Acta; 2014 Aug; 1842(8):1273-81. PubMed ID: 24225420 [TBL] [Abstract][Full Text] [Related]
22. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study. Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881 [TBL] [Abstract][Full Text] [Related]
23. Mouse models for LRRK2 Parkinson's disease. Xu Q; Shenoy S; Li C Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430 [TBL] [Abstract][Full Text] [Related]
24. Role of LRRK2 in the regulation of dopamine receptor trafficking. Rassu M; Del Giudice MG; Sanna S; Taymans JM; Morari M; Brugnoli A; Frassineti M; Masala A; Esposito S; Galioto M; Valle C; Carri MT; Biosa A; Greggio E; Crosio C; Iaccarino C PLoS One; 2017; 12(6):e0179082. PubMed ID: 28582422 [TBL] [Abstract][Full Text] [Related]
25. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Xiong Y; Dawson VL; Dawson TM Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868 [TBL] [Abstract][Full Text] [Related]
26. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. Johnson J; Paisán-Ruíz C; Lopez G; Crews C; Britton A; Malkani R; Evans EW; McInerney-Leo A; Jain S; Nussbaum RL; Foote KD; Mandel RJ; Crawley A; Reimsnider S; Fernandez HH; Okun MS; Gwinn-Hardy K; Singleton AB Neurodegener Dis; 2007; 4(5):386-91. PubMed ID: 17622782 [TBL] [Abstract][Full Text] [Related]
27. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation. Kamikawaji S; Ito G; Sano T; Iwatsubo T Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436 [TBL] [Abstract][Full Text] [Related]
36. [Advance of the study on LRRK2 gene in Parkinson's disease]. Zhang Y; Chen S Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525 [TBL] [Abstract][Full Text] [Related]
37. Absence of commonly reported leucine-rich repeat kinase 2 mutations in Eastern Indian Parkinson's disease patients. Sanyal J; Sarkar B; Ojha S; Banerjee TK; Ray BC; Rao VR Genet Test Mol Biomarkers; 2010 Oct; 14(5):691-4. PubMed ID: 20722494 [TBL] [Abstract][Full Text] [Related]
38. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant. Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766 [TBL] [Abstract][Full Text] [Related]
39. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease. Lu YW; Tan EK J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801 [TBL] [Abstract][Full Text] [Related]
40. LRRK2 signaling pathways: the key to unlocking neurodegeneration? Berwick DC; Harvey K Trends Cell Biol; 2011 May; 21(5):257-65. PubMed ID: 21306901 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]